Opstarten insuline/GLP-1 door Dr. Evy Degrande - haowvl

� Both meta-analyses show consistent CV benefit with intensive
glucose lowering 1,2 :
� HbA 1c reduction with ~5 years of follow-up was 0.9%
� 15–17% risk reduction (RR) for MI
� 9% and 15% RR for CV and CHD events, respectively
� No increased risk of stroke or all-cause mortality
Practical clinical implications
Initiate therapy early, before any micro- or macrovascular
disease
Reduce HbA 1c steadily with care to avoid hypoglycaemia
A combination of glucose-lowering agents may be needed to
achieve lower glycaemic targets
1. Ray KK, et al. Lancet. 2009;373:1765-72. 2. Turnbull FM, et al. Diabetologia. 2009;52:2288-98.